scholarly journals Hormone receptor expression in human fascial tissue

2016 ◽  
Author(s):  
C. Fede ◽  
G. Albertin ◽  
L. Petrelli ◽  
M.M. Sfriso ◽  
C. Biz ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Hormone Receptor ◽  
Hormone Receptors ◽  
Myofascial Pain ◽  
Sex Hormone ◽  
Receptor Expression ◽  
Adult Women ◽  
Hormonal Factors ◽  
Hormone Receptor Expression ◽  
Post Menopausal

Many epidemiologic, clinical, and experimental findings point to sex differences in myofascial pain in view of the fact that adult women tend to have more myofascial problems with respect to men. It is possible that one of the stimuli to sensitization of fascial nociceptors could come from hormonal factors such as estrogen and relaxin, that are involved in extracellular matrix and collagen remodeling and thus contribute to functions of myofascial tissue. Immunohistochemical and molecular investigations (real-time PCR analysis) of relaxin receptor 1 (RXFP1) and estrogen receptor-alpha (ERα) localization were carried out on sample of human fascia collected from 8 volunteers patients during orthopedic surgery (all females, between 42 and 70 yrs, divided into pre- and post-menopausal groups), and in fibroblasts isolated from deep fascia, to examine both protein and RNA expression levels. We can assume that the two sex hormone receptors analyzed are expressed in all the human fascial districts examined and in fascial fibroblasts culture cells, to a lesser degree in the post-menopausal with respect to the pre-menopausal women. Hormone receptor expression was concentrated in the fibroblasts, and RXFP1 was also evident in blood vessels and nerves. Our results are the first demonstrating that the fibroblasts located within different districts of the muscular fasciae express sex hormone receptors and can help to explain the link between hormonal factors and myofascial pain. It is known, in fact, that estrogen and relaxin play a key role in extracellular matrix remodeling by inhibiting fibrosis and inflammatory activities, both important factors affecting fascial stiffness and sensitization of fascial nociceptors.

Sex Hormone Receptor Expression in the Human Vocal Fold Subunits

2017 ◽  
Vol 31 (4) ◽  
pp. 476-482 ◽  
Author(s):  
Tolga Kirgezen ◽  
Ahmet Volkan Sunter ◽  
Ozgur Yigit ◽  
Gulben Erdem Huq
Keyword(s):  
Hormone Receptor ◽  
Vocal Fold ◽  
Sex Hormone ◽  
Receptor Expression ◽  
Sex Hormone Receptor ◽  
Hormone Receptor Expression

scholarly journals Breast MALT Lymphoma: Potential Relationship Between Hormonal Environment and Female Sex Hormone Receptor Expression in Lymphoma Cells

2001 ◽  
Vol 42 (5) ◽  
pp. 1157-1159 ◽  
Author(s):  
Yusuke Hakoda ◽  
Akihiko Gotoh ◽  
Yuzuru Kuriyama ◽  
Mikio Kusama ◽  
Yasuhisa Koyanagi ◽  
...  
Keyword(s):  
Malt Lymphoma ◽  
Hormone Receptor ◽  
Sex Hormone ◽  
Receptor Expression ◽  
Lymphoma Cells ◽  
Female Sex ◽  
Potential Relationship ◽  
Sex Hormone Receptor ◽  
Hormone Receptor Expression

Large angioleiomyoma, rich of mast cell and sex hormone receptor expression

2008 ◽  
Vol 279 (2) ◽  
pp. 193-197 ◽  
Author(s):  
Masaru Hayashi ◽  
Shigeki Tomita ◽  
Ichio Fukasawa ◽  
Noriyuki Inaba
Keyword(s):  
Mast Cell ◽  
Hormone Receptor ◽  
Sex Hormone ◽  
Receptor Expression ◽  
Sex Hormone Receptor ◽  
Hormone Receptor Expression

Prognostic relevance of partial hormone receptor expression in stage I breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11021-e11021
Author(s):  
Ariel Zwenger ◽  
Julieta Leone ◽  
Julian Iturbe ◽  
Palmira Perez Verdera ◽  
Jose Pablo Leone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hormone Receptors ◽  
Receptor Expression ◽  
Stage I ◽  
Distant Failure ◽  
Prognostic Assessment ◽  
Hormone Sensitive ◽  
Hormone Receptor Expression

e11021 Background: Patients whose tumors express only one hormone receptor (1HR) are usually considered hormone-sensitive regarding treatment decisions. However, certain retrospective analyses suggest that patients bearing ER+/PR- or ER-/PR+ tumors may have worse outcomes than those with ER+/PR+ (HR) phenotype. The aim of this study was to correlate partial expression of hormone receptors (ER+/PR- or ER-/PR+) with several well known prognostic factors and their possible influence on the incidence of local and distant failure, relapse free survival (RFS) and overall survival (OS) in women with early breast cancer treated at GOCS institutions. Methods: We evaluated 327 patients with stage I breast cancer (T1a,b,cN0M0; AJCC 2010) diagnosed between January 1991 and December 2009. Further analyses were conducted upon a cohort of 282 patients who were divided between those whose tumors expressed both HR and those with only 1HR. Results: The median age was 54.2 years (29-89). Median follow-up was 9.4±4.4 years (0.2-22.9). Both HR and 1HR were expressed in 242 and 40 patients respectively. Similar adjuvant treatment was administered in both groups although the number of mastectomies was higher in the subgroup with only 1HR (22.5% vs. 5.8%, P =. 0003). Univariate analyses showed no difference between both groups when correlated with age, body mass index, histologic type, T stage, histologic and nuclear grade, mitotic index, vascular invasion, necrosis and margin status. However, 1HR tumors had a higher rate of lymphovascular invasion (21.9% vs. 9.5%, P =.038) and HER2 expression (57.1% vs. 21.9%, P = .035). Treatment failure was more frequent in patients with only 1HR (12.5% vs. 5%, P =.064). Distant progression was also more common in this subgroup (80% vs. 58.3%, P =.334). There were no statistically significant differences in RFS and OS among groups. Conclusions: The expression of only 1HR constitutes a phenotype that could have a more aggressive biology and be associated with higher risk of recurrence than tumors with both receptors. Analysis of more patients, larger tumor size and N1 disease is warranted to confirm this hypothesis and have a better prognostic assessment.

scholarly journals A case report of bladder and intestinal endometriosis, and the relationship between sex hormone receptor expression and PIK3CA mutation analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Akiko Kanto ◽  
Yasushi Kotani ◽  
Kosuke Murakami ◽  
Chiho Miyagawa ◽  
Hidekatsu Nakai ◽  
...  
Keyword(s):  
Progesterone Receptor ◽  
Hormone Receptor ◽  
Pik3ca Mutation ◽  
Sex Hormone ◽  
Receptor Expression ◽  
Tubular Structures ◽  
Sex Hormone Receptor ◽  
Rare Site ◽  
Hormone Receptor Expression

Abstract Background Extragonadal endometriosis is a rare condition, and its disease manifestation and long-term prognosis have not been elucidated. We report an extragonadal endometriosis case controlled by drug therapy for 14 years with analysis of the sex hormone receptor expression and PIK3CA mutation. Case presentation The patient was diagnosed with bladder endometriosis at age of 30 years, and underwent bilateral nephrostomy and GnRHa therapy with add-back therapy. The patient was switched to dienogest therapy at age 35 and had hematuria and bloody stools at age 38. PET-CT revealed a 6-cm mass in the bladder with fluorodeoxyglucose accumulation and the diagnosis of endometriosis in the bladder, sigmoid colon, and cecum was confirmed after the biopsy result. The lesion’s tubular structures were positive for the estrogen receptor, but only 30% positive for the progesterone receptor, and the H1047R mutation in PIK3CA was found in tubular structures of the bladder lesion. GnRHa therapy caused the tumors to shrink. Conclusion Decreased progesterone receptor expression and oncogenic mutations may influence the course of less common and rare site endometriosis. Rare site endometriosis often requires long-term hormone therapy, and management should be tailored to the patient's life stage, keeping in mind complications, such as decreased bone density.

Sign in / Sign up

Export Citation Format

Share Document